SCHEMBL6956094

SCHEMBL6956094

O=c1oc(-c2ccccc2O)cc(O)c1SCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 1/20 0.46
AKR1C2 P52895 1/20 0.46
AKR1C1 Q04828 1/20 0.46
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
TP53 P04637 4/20 0.43
HPGD P15428 3/20 0.43
ALOX15 P16050 3/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
DAO P14920 3/20 0.41
CYP3A4 P08684 5/20 0.40
CYP2C19 P33261 5/20 0.40
MAPT P10636 5/20 0.40
CYP2D6 P10635 4/20 0.40
CYP2C9 P11712 4/20 0.40
KDM4E B2RXH2 2/20 0.40
RECQL P46063 2/20 0.40
HSD17B10 Q99714 2/20 0.40
TDP1 Q9NUW8 2/20 0.40
ALDH1A1 P00352 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6961428 0.88 MEN1 (0.45) MEN1KMT2AHPGDSMN1; SMN2DAO
SCHEMBL6958994 0.88 HPGD (0.45) KMT2AHPGDSMN1; SMN2DAOMAPT
SCHEMBL6954786 0.86 SMN1; SMN2 (0.50) MEN1KMT2ATP53HPGDALOX15
SCHEMBL6954509 0.83 NPC1 (0.47) MEN1KMT2AHPGDSMN1; SMN2DAO
SCHEMBL6959887 0.81 S100A4 (0.36) HPGDDAOMAPTKDM4ETSHR
SCHEMBL6960015 0.81 ELANE (0.44) KMT2AHPGDSMN1; SMN2DAOMAPT
SCHEMBL6960796 0.81 TNKS (0.47) MEN1KMT2ATP53HPGDALOX15
SCHEMBL6963367 0.81 POLB (0.45) HPGDSMN1; SMN2DAOMAPTKDM4E
SCHEMBL6963460 0.81 EGFR (0.41) KMT2AHPGDSMN1; SMN2DAOCYP2C19
SCHEMBL6963454 0.80 ALOX5 (0.43) SMN1; SMN2DAOMAPTTDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US claimed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP claimed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO claimed
EP-0729465-B1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE DAVIS & CO (US) 2003-01-22 EP disclosed
US-6005103-A TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS WARNER-LAMBERT COMPANY (US) 1999-12-21 US disclosed
US-5808062-A AIDS THERAPY WARNER-LAMBERT COMPANY (US) 1998-09-15 US disclosed
EP-0729466-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
EP-0729465-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1996-09-04 EP disclosed
WO-1995014013-A1 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed
WO-1995014014-A2 PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS PARKE, DAVIS & COMPANY (US) 1995-05-26 WO disclosed